Trials / Withdrawn
WithdrawnNCT03216486
An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
A Phase 2, Non-controlled, Open-Label, Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Ultragenyx Pharmaceutical Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effect of BPS804 on strength/quality of bone in patients with Type I, III or IV Osteogenesis imperfecta using a special type of CT scanner. Participants will be treated for 1 year.
Detailed description
This study was previously posted by Mereo Biopharma and was transferred to Ultragenyx in February 2021.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPS804 | IV administration of BPS804 in 5% Dextrose solution |
Timeline
- Start date
- 2017-10-31
- Primary completion
- 2018-11-01
- Completion
- 2018-11-01
- First posted
- 2017-07-13
- Last updated
- 2023-07-03
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03216486. Inclusion in this directory is not an endorsement.